Subsequent, in vivo experimental results showed that the combination of BBI608 and paclitaxel could decrease tumour burden and ascites volume better than monotherapy by blocking the activation of Stat3 and increasing cleaved caspase‐3‐positive cells’ number without detectable toxicity in a peritoneal metastasis mouse model. This evidence concerns the gene STAT3 and neoplasm.